During the past decade, Werken Glorieux VZW conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 2 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Werken Glorieux VZW" are "Carcinoma, Non-Squamous Non-Small Cell Lung" (1 trials) and "Squamous Non-Small Cell Lung Cancer" (1 trials). Many other conditions were trialed in "Werken Glorieux VZW" in a lesser frequency.

Most popular intervention types in "Werken Glorieux VZW" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (2 trials), "Nab-Paclitaxel" (2 trials), "Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody" (1 trials), "Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody" (1 trials) and "Paclitaxel" (1 trials). Other intervention names were less common.

The vast majority of trials in "Werken Glorieux VZW" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Werken Glorieux VZW". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Werken Glorieux VZW, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Werken Glorieux VZW, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".